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ABSTR ACT: Modern medicine faces a growing crisis as demand for organ transplantations continues to far outstrip supply. By stimulating the body’s 
own repair mechanisms, regenerative medicine aims to reduce demand for organs, while the closely related field of tissue engineering promises to deliver 
“off-the-self ” organs grown from patients’ own stem cells to improve supply. To deliver on these promises, we must have reliable means of generating com-
plex tissues. Thus far, the majority of successful tissue engineering approaches have relied on macroporous scaffolds to provide cells with both mechanical 
support and differentiative cues. In order to engineer complex tissues, greater attention must be paid to nanoscale cues present in a cell’s microenvironment. 
As the extracellular matrix is capable of driving complexity during development, it must be understood and reproduced in order to recapitulate complexity 
in engineered tissues. This review will summarize current progress in engineering complex tissue through the integration of nanocomposites and biomi-
metic scaffolds. 
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Introduction
The ability to regenerate damaged tissues is a common feature 
across species’. While salamanders may regenerate entire 
limbs, humans are limited in meaningful regeneration of func-
tional tissue to specialized organs such as the liver.1 The pos-
sibilities of harnessing tissue regeneration in human medicine 
have not been lost on the medical and scientific professions 
since Réaumuer first described the regeneration of a crayfish 
claw in 1712.2
Over the past two decades, Anthony Atala, Robert 
Langer, and others have pioneered the fields of tissue engi-
neering and regenerative medicine. Breakthroughs such as 
Atala’s neobladder,3 and more recently, a pilot study of tissue-
engineered autologous vaginal organs,4 come at a time when 
the world is facing a looming organ transplantation crisis as 
demand continues to far outstrip supply.5,6 Continued advances 
in regenerative medicine promise a means to stimulate the 
body’s own repair mechanisms to regenerate damaged tissue. 
Furthermore, the use of patient-derived stem cells to provide 
“off-the-self ” organs grown in vitro offers an alternative to life-
long immunosuppressive drugs for transplant patients in a post-
antibiotic age.
Strategies for regenerative medicine. Towards regenera-
tive medicine in humans—the process of replacing, engineer-
ing, or regenerating human cells, tissues, or organs to restore 
or establish normal function7—there are currently three broad 
strategies. Perhaps the most synonymous with regenerative med-
icine are the stem cell therapies. As stem cells are responsible for 
engineering an organ’s original complexity during development, 
it holds that they should be capable of recapitulating complexity 
Cassidy
26 Bone and Tissue RegeneRaTion insighTs 2014:5
after injury. Although recent advances in the field show great 
promise,8–11 much work is still required before such therapeutic 
strategies are available to the vast majority of patients.
In animals capable of tissue regeneration, stem and pro-
genitor cells first organize into a blastema at the site of injury.12 
One theory holds that the immune system of adult mammals 
precludes regeneration by inhibiting this arrangement, and 
instead, shows a strong bias for fast recovery and early return 
of movement.13 Hence, another prominent strategy in tissue 
engineering aims to modulate the immune system to allow 
endogenous regeneration.14 In fact there is a strong correlation 
between the development of adaptive immunity and the loss 
of regenerative ability.15 However, this is currently no more 
than a correlation, and other evidences point to a positive role 
for the immune system in regeneration. For example, there is 
strong evidence that the complement protein C5 modulates 
the release of pro-regenerative Interleukin-6 (IL-6) from 
Kupffer cells during liver regeneration in mammals16 and C5 
is expressed in the newt blastema during limb and lens regen-
eration,17 pointing to a common role across species.
Despite an incomplete understanding of the processes 
involved in regeneration, progress has been made in apply-
ing the principles of regenerative medicine to humans, and 
with a more complete understanding of the limited regenera-
tive capacity of humans, new insights will increase the scope 
of stem cell therapies.8 However, currently these purely cell-
based therapies are limited, not the least by the fear of tera-
toma formation. At present, the majority of successful tissue 
engineering projects have relied on macroporous scaffolds to 
facilitate both initial attachment and subsequent differentia-
tion cues for seeded stem cells. While successful for relatively 
simple tissues such as blood vessels18 and bladders,3 complex 
metabolic organs such as the liver and kidneys will require 
more sophisticated biomimetic scaffolds capable of providing 
multilayer information to differentiating cells.19
To deliver on the promise of “off-the-self ” organs and to 
successfully stimulate in vivo tissue regeneration, the grow-
ing field of nanomedicine must be integrated into the tissue 
engineering approach (Fig. 1). This review aims to summarize 
some of the key current examples of integrated nanotechnol-
ogy in regenerative medicine and tissue engineering, as well 
as highlighting some of the most promising future directions. 
Specifically, this article will discuss how nanotechnology is 
integrated into scaffolds for tissue engineering in order to 
mimic a tissue’s natural extracellular matrix (ECM). Equally 
important areas of research encompassing both nanotechnol-
ogy and regenerative medicine, eg, nanoparticle drug delivery, 
fall out of the scope of this article and will not be discussed.
The Extracellular Microenvironment: Driving 
Complexity
In the body, a cell’s direct microenvironment is composed 
of an intricate three-dimensional (3D) network of fibrillar 
proteins, proteoglycans, and glycosaminoglycans (GAGs), 
collectively termed the extracellular matrix (ECM). Each tis-
sue has a unique ECM composition and topology generated 
through a dynamic biomechanical and biophysical dialog 
between various cell lineages and their respective microenvi-
ronments.20 Far from simply providing mechanical support, 
the ECM provides an environment rich in topographical, 
mechanical, and biochemical cues capable of guiding a het-
erogeneous population of cells into a functional organ during 
development.21
Furthermore, it is becoming apparent that both cells and 
ECM are absolutely required to define a specific tissue. For 
example, bone and cartilage are primarily composed of ECM, 
encapsulating a small number of cells. In bone, a mineralized 
ECM confers the typical rigidity, whereas in soft cartilage, 
chondrocytes are entrapped in a highly hydrated ECM, which 
allows movement.22 Likewise, collagens in our ligaments and 
tendons are secreted along their major axis, conferring resis-
tance to load and strain, whereas collagens in the intestine 
are arranged in a cylindrical fashion to allow for coordinated 
peristalsis.23 Often, removal or substitution of the ECM leads 
not only to the loss of structure but also to the complete loss of 
function or even viability.24
In a seminal paper presented by Allan Hall25 the role for 
focal adhesion formation and integrin signaling on cell fate 
was cemented. Work since then has shown how mesenchy-
mal stem cell (MSC) adhesions can be manipulated to either 
efficiently form bone26 or maintain multipotency.27 The fact 
that such diverse cell fates can be controlled by slight surface 
manipulation highlights the complex relationship between 
cells and matrix. Through reciprocal action (cells depositing 
matrix, influencing cell fate, and controlling deposition of new 
matrix), tissues can exist in dynamic equilibrium, be highly 
Figure 1. Venn diagram showing the crossover between tissue-specific 
eCM and advances in nanotechnology. as manufacturing techniques 
improve, eg, advances in photolithography, higher resolution, and 
more biomimetic scaffolds become available. similarly, as knowledge 
of the natural tissue eCM improves, currently available techniques can 
be utilized to better mimic the natural eCM. in the overlap between 
nanotechnology, manufacturing techniques, and knowledge of the natural 
eCM lays the possibility of successful biomimetic scaffold design for 
nanotechnology.
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sensitive to slight changes in the local and systemic milieu, and 
be able to adjust accordingly through growth factor sequestra-
tion and the development of morphogen gradients.28 In order 
to successfully engineer a complex tissue, the microscale and 
nanoscale features (Fig. 2) of such a matrix must be under-
stood in a tissue-specific context.
Materials to Mirror the ECM
As our understanding of a cell’s interaction with its microen-
vironment becomes clearer, the need for appropriate nanoscale 
physiochemical cues to guide cell attachment and differentia-
tion has become obvious. In general, scaffolds should aim to 
recapitulate specific parameters and components of the tis-
sue-specific ECM while retaining structural and mechanical 
support for cells and organs. Various manufacturing tech-
niques, primarily under development in the electronics indus-
try, have been employed in the creation of tissue engineering 
scaffolds. Table 1 provides a brief overview of key techniques, 
and for a detailed review, see Engel et al.29
Perhaps one of the most advanced uses of nanotechnol-
ogy in tissue engineering is the patterning of implantable 
surfaces with nanotopographies. Polymer demixing, chemi-
cal etching, and colloidal lithography are some of the most 
relevant techniques for producing random patterns favored by 
osteoblasts on bone implants,26,30,31 whereas soft-lithography 
techniques are better suited for producing regular geometries.
As a bridge between tissue engineering and providing 
the required mechanical support, nanopatterning of orthope-
dic surfaces has shown great benefit.32 However, engineering 
complex tissues will require complex 3D scaffolds to become a 
reality. Some of the most common structures used in experi-
mental tissue engineering aim to mimic the fibrous phase of 
the ECM, composed of collagens and elastins. Electrospin-
ning has emerged as a versatile technique, capable of creat-
ing complex 3D cell scaffolds from synthetic polylactic acid 
(PLA), polyglycolic acid (PGA), poly(lactic-co-glycolic acid) 
(PLGA)33 and natural (silk, collagen, and chitosan)34 materi-
als, while requiring a relatively basic set up.35
Numerous techniques are available to further functional-
ize the 3D microfibrous and nanofibrous scaffolds created by 
electrospinning (see Tables 1 and 2). For example, to mimic the 
presence of adhesion proteins such as laminins and fibronectins 
within the matrix, Arg-Gly-Asp (RGD) peptide sequences 
can by conjugated to the matrix backbone to  promote and con-
trol cell adhesion.36,37 Furthermore, isoleucine-lysine-valine- 
alanine-valine (IKVAV) laminin  adhesion sequences have 
been conjugated to PLA electrospun nanofibers to promote 
neurite regrowth in models of peripheral nervous repair.38 
Beyond conjugation of adhesion motifs, various methods 
have been established to functionalize the matrix backbone, 
including sulfating with perlecan or chitosan to control the 
presentation of growth factors39,40 and adding tissue-specific 
minerals such as hydroxyapatite to induce osteogenesis and 
mineralization in bone repair.41,42
State of the art. Molecular self-assembly has been one 
of the most exciting recent developments in the field of bio-
material research. Peptides amphiphiles can produce ther-
modynamically stable structures with final properties readily 
tunable by molecular chemistry (altering pH, solvents, tem-
perature, etc.).43 By adjusting the initial monomers (eg, by 
patterning with IKVAV sequences)44 and the assembly condi-
tions, complex structures can be produced in an entirely free 
energy–driven process. These structures have the capacity to 
present multiscale information to cells with exquisite levels of 
control. A major current limitation is in the lack of mechani-
cal strength; however, there is the possibility of utilizing 
nanocomposites to compensate for such scaffold limitations 
(Table 2). For example, carbon nanotubes show viscoelastic 
behavior similar to that observed in soft-tissue membranes45 
and have been used to increase the Young’s modulus and tensile 
strength of hybrid biomaterials.46 An excellent review of self-
assembling peptide amphiphiles has been published by Sam-
uel Stupp and colleagues at the Northwestern University.43
Cardiac Tissue
Clinical need. Heart disease is the leading cause of 
death worldwide. Although incidence in the developed world 
is reducing, this is countered by an overall increase in many 
developing countries. Although not a cure for heart disease, 
cardiac transplant surgery is a life-saving procedure for the 
most severe cases of heart failure.47 Of the 3,500 world-
wide transplant procedures carried out annually, 2,000 are 
performed in the United States, pointing to a potential rise 
in demand as developing countries mature. In 2007, it was 
Macroscale Microscale Nanoscale Picoscale
Figure 2. Micro- and nanoscales in nature. Cells are in the order of a hundred nanometers, they interact with proteins and molecules of nano- and 
picoscale dimensions to form tissues and organs of micro- and macroscale.
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estimated that 50,000 people were awaiting heart transplan-
tation worldwide.48 The vast disparity between the number 
of required procedures and the number performed annually, 
together with rising demand from developing countries, has 
driven research into both bioartificial and xenograft alterna-
tives. To date, neither of these approaches is as effective as 
traditional tissue-typed allograft procedures.49
Cardiac ECM. The heart wall is composed of tightly 
packed fibrillar collagen and elastin bundles that form a dense, 
elastic network ranging from 10 to several hundreds of nano-
meters across. This dense mesh is covered with nanoscale adhe-
sive proteins such as laminin and fibronectin, allowing cells to 
interact through integrins and cadherins on their surface.50 The 
high metabolic demand of the heart muscle means that it con-
sumes large amounts of oxygen and cannot tolerate hypoxia. It 
is therefore highly perfused by a supporting network of vascu-
lature. This dense, but defined network, confers on the heart its 
unique mechanical and electrical properties as cardiomyocytes 
are forced to couple with each other in a 3D syncytium of elon-
gated and aligned cell bundles (Fig. 3).51
Tissue engineering approaches. In 2008, Ott and 
co-workers reported a study emphasizing the importance of 
the ECM in guiding essential morphological organization and 
physiological function by engineering a bioartificial rat heart.52 
By decellularizing adult rat hearts by coronary perfusion with 
detergents, the researchers were able to preserve the underlying 
ECM. When reseeded with cardiac and endothelial cells, the 
ECM guided self-organization and allowed restoration of pump 
function. In contrast, when seeded on a flat scaffold, cardiomy-
ocytes lost their elongated morphology and adopted a random 
distribution, which compromised many of their physiological 
functions. In an attempt to mimic the in vivo ventricular struc-
ture, Kim and colleagues cultured cardiac cells on polyethylene 
glycol hydrogel–grooved arrays with widths ranging from 50 
to 800 nm.53 Guided by the nanoscale mechanical cues, these 
tissue constructs displayed anisotropic action potential propa-
gation and produced the aligned contractility essential for heart 
function. Although this paper made important advances, the 
difficulty of patterning such arrays within 3D scaffolds remains, 
and hence, the utility of such techniques remains to be proven.
Table 1. Typical scaffold manufacturing techniques.
ELECTROSPINNING PHOTOLITHOGRAPHY DIP-PEN NANO  
LITHOGRAPHY
MICROCONTACT  
PRINTING 
Maximum Resolution 5 nm–1 μm 37 nm 20–30 nm 35 nm–1 μm
advantages easy set up, versatile  
materials, high relevance 
to eCM
Precise control and introduction 
of defined disorder 
Precise control of complex 
patterns and growth factor  
gradients 
Flexibility of printed  
materials, print on  
non-planar surfaces
disadvantages Poor mechanical properties 
with most materials 
Photosensitive compounds  
used, potentially toxic and very  
expensive to set up
small areas only Low control over  
ligand density
schematic
Reference 55,88 26,27,30 89 90
 
Table 2. nanocomposites to compensate for matrix limitations.
NANOCOMPOSITE MATERIAL EFFECT ON MATRIX REFERENCE
Carbon nanotubes 
increase Young’s modulus and tensile strength,  
overcoming weak matrix mechanical properties
46
increased matrix conductivity 91
synthetic nanospheres
allow controlled release of morphogens and biomolecules 92
Magnetic nanoparticles to aid vascular tissue  
engineering—control over shape
93
nanotitanite wires improve cell matrix interactions and increases  cell adhesion 
94
gold nanowires allow precise control over biomolecule localization  within a scaffold 
95
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One radically different approach to engineering 
cardiac tissue involves the creation of stackable cell sheets. 
Shimizu and colleagues reported a method of culturing rat 
neonatal ventricular myocytes on temperature-sensitive 
poly(N-isopropylamide) surfaces.54 At 37°C, these surfaces 
support normal cell adhesion and growth; however, at 32°C 
they become hydrophobic and cease to support cell adhesion. 
Through this method, the researchers were able to remove 
entire monolayers of electrically coupled cardiomyocytes, 
without loss of cell–cell contacts through trypsinization. 
Monolayers could then by stacked and grafted onto defects 
created in rat hearts in vivo, where they showed coordinated 
depolarization and contraction in synchrony with the native 
tissue. Perhaps unsurprisingly from what we know of the 
highly vascularized nature of cardiac tissues, this process was 
limited to sheet thicknesses of around 80 μm. A major limita-
tion of nonscaffold techniques such as these is the lack of tis-
sue perfusion; clearly to have clinical relevance for correcting 
defects in human myocardium, these types of processes must 
be adapted to promote angiogenesis.
Montero and colleagues recently reported increased 
sprouting in an in vitro angiogenesis assay when Human 
Figure 3. schematic of cardiomyocyte interaction with the eCM (A). Tightly wound collagen and elastin bundles force an elongated cell morphology and 
cell coupling through gap junctions. similar cellular organization can be seen in vitro by culturing cardiomyocytes on nanometric-grooved topographies. 
shown for illustration are endothelial cells (B) exhibiting contact guidance when cultured on 240-nm–grooved arrays (C). immunocytochemistry: Red is 
actin, green is vinculin, and blue is daPi (nuclear).
Cassidy
30 Bone and Tissue RegeneRaTion insighTs 2014:5
Umbilical Vein Endothelial Cells (HUVECs) were seeded 
onto an electrospun gelatin scaffold with aligned nanoarchi-
tectural features and embedded basic fibroblast growth factor 
(bFGF).55 Electrospinning techniques can also be employed 
to coat surfaces in aligned fibers.56 Although yet to be experi-
mentally validated, cardiomyocytes could be seeded in mono-
layer with nanoscale gelatin fibers and bFGF, potentially 
creating cell sheets primed for angiogenesis in vivo. Taking 
this further, cells could be seeded onto a surface containing 
sacrificial carbohydrate glass channels, and in vivo these chan-
nels could be aligned to provide a cell-free conduit for efficient 
neoangiogenesis driven by bFGF.57
Tissue engineering heart valves. Beyond the regen-
eration of a functional myocardium, a substantial amount of 
research is geared toward construction of tissue-engineered 
heart valves in vitro. Each year in the United States, 85,000 
artificial (requiring chronic anticoagulant therapy) or animal-
derived (prone to calcification) valves are implanted, repre-
senting a substantial clinical need.58 Characterization of the 
decellularized basement membrane of porcine aortic valves 
by Brody and colleagues revealed a matrix of fibers and pores 
with respective diameters of 30 and 22  nm.59 An optimum 
tissue engineering strategy should therefore comprise a cel-
lularized nanoscale substrate of similar scale.60
Consistent with the limited progress in recapitulating 
the natural ECM, by far the most advanced clinical studies 
involving bioartificial heart valves have used decellularized 
allografts. One early study presented by Dohmen and col-
leagues used a decellularized pulmonary allograft seeded with 
autologous endothelial cells and conditioned in a bioreactor to 
reconstruct the right ventricular outflow tract of adults under-
going the Ross procedure.61 Medium and long-term follow-ups 
have been published, showing that most valves retain excellent 
hemodynamic profiles, and all patients were alive, and showing 
New York Heart Association class I after 10 years.62,63 Clearly, 
these procedures were life changing for the patients involved, 
but without detracting from this study’s impact, the ultimate 
goal remains the creation of completely autologous organs.
Tissue Engineering the Liver
Clinical need. Liver disease and subsequent loss of liver 
function is currently the 12th most frequent cause of death 
in the United States.64 Liver transplantation is the only ther-
apy proven to improve mortality, but despite recent advances 
in surgical techniques (split transplants, living related partial 
donor procedures), the situation remains acute.65 Beyond global 
trends in organ transplantation, liver disease in particular suf-
fers from compounding factors including the emergence of 
new liver diseases such as steatohepatitis and an aging popula-
tion of hepatitis patients at risk of progression to hepatocellular 
carcinoma.66 Like the other pathologies discussed, the short-
age of donor organs remains acute despite improvements in 
allocation, suggesting that liver transplantation procedures 
alone will not be able to meet any increased demand.
Epithelial tissue ECM. The dense and highly aligned 
ECM seen in cardiac tissues is not a ubiquitous requirement in 
the development of complex tissues. In a stark contrast to the 
cardiac syncytium, epithelial tissues such as those in the liver, 
kidneys, and pancreas comprise a unique schema of polarized 
cell contacts. For example, in the liver, each hepatocyte has 
a basal surface contacting the ECM, an apical surface fac-
ing the lumen, and a lateral surface in contact with other cells 
(Fig. 4). Like the heart, the cellular organization and hierar-
chy is directly relevant to the organ’s function and completely 
guided by the ECM.67 Cells lacking luminal contact will be 
unable to contribute to secretion or absorption into surround-
ing capillaries and will undergo apoptosis to create a luminal 
space.68 Hence, scaffolds should aim to recapitulate the nano-
metric ECM in order to guide cells into a highly perfused 
columnar structure (Fig. 5).
Tissue engineering approaches. In order to create a bio-
artificial liver (BAL) system for in vivo transplantation, it is 
necessary to recapitulate the complex 3D nanotopography of 
the liver ECM using defined or artificial matrices. The com-
plex architecture of the liver ensures proper oxygenation of 
the metabolically hyperactive hepatocytes alongside efficient 
nutrient exchange and liver-specific functions (ammonia 
detoxification, albumin secretion, urea metabolism, etc.).69 
BAL systems must promote culture on nonxenogenic surfaces 
of defined topography, with excellent means of nutrient 
exchange and blood detoxification.70
To create functional tissues able to undergo efficient dif-
fusion to and from adjacent lumens, Bettinger and colleagues 
Figure 4. Basic structure of a liver lobule, each hepatocyte has a basal 
surface contacting the eCM, an apical surface facing the lumen, and 
a lateral surface in contact with other cell. Like the heart, the cellular 
organization and hierarchy is directly relevant to the organ’s function 
and completely guided by the eCM.67
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created poly(ester amide) substrates nanopatterned with 
pillar diameters between 260 and 410 nm.71 In doing so, the 
researchers were able to mimic the cross-sectional dimen-
sions of collagen fibrils and enhance the attachment and 
proliferation of hepatocytes in vitro. Crucially, metabolic 
function was increased in hepatocytes cultured on such sub-
strates. To ensure formation of appropriate lumens, Feng and 
colleagues took this concept further by culturing hepatocytes 
on nanofibrous galactosylated chitosan scaffolds and were 
able to show increased levels of liver-specific functions.72 
The rationale behind fibrous hepatocyte scaffolds is shown 
diagrammatically in Figure 5.
Several attempts have been made to scale up knowledge 
of hepatocyte culture in two-dimensions (2D) into 3D scaffold 
systems. Synthetic hydrogels based on poly(ethylene glycol) 
(PEG) have been studied extensively for tissue engineering 
Figure 5. Schematic showing a tissue engineering strategy for liver cells based on electrospun nanofibers. The high metabolic demand and liver-specific 
functions (absorption, detoxification, etc.) of hepatocytes requires a highly perfused tissue structure. Electrospun scaffolds (lower panel) allow excellent 
hepatocyte perfusion and are desirable options for BaL–assisted devices, tissue engineering for liver regeneration, and hepatocyte culture for drug 
safety analysis. In a series of studies, Feng and colleagues have developed one such method based on chitosan nanofibers in an attempt to mimic the 
natural liver lobule structure.72,96 Bar is 25 μm. The diagrams in this figure are adapted from OpenStax College, Anatomy & Physiology. OpenStax CNX. 
Jul 31, 2014. http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e22@6.27@6.27.
Cassidy
32 Bone and Tissue RegeneRaTion insighTs 2014:5
approaches73 and have found recent utility in 3D liver 
platforms. Liu Tsang and colleagues incorporated RGD pep-
tide sequences into photopolymerizable PEG hydrogels, which 
could be polymerized into a complex 3D architecture in the 
presence of primary hepatocytes.74 Selective cell adhesion to 
RGD sequences ensured microscale channels throughout the 
scaffold, minimizing barriers to nutrient exchange by these 
highly metabolic cells.
In a similar attempt to preserve liver function in a 
defined 3D environment, Giri and colleagues have recently 
reported a clinically relevant bioreactor culture system for 
primary rat hepatocytes based on a self-assembling peptide 
nanoscaffold.69 Here the authors sought to mimic the complex 
nanotopography of a hepatocyte basement membrane while 
minimizing the use of any xenogenic, nondefined, or toxic 
materials.
Incentive to create a biomimetic hepatocyte culture 
system also exists from the pharmaceuticals industry. In 
an attempt to improve on existing methods of toxicol-
ogy screening, Lee and colleagues have described a novel 
hepatocyte culture device based on microfluidic channels 
etched by photolithography.75,76 Here, liver microsomes are 
encapsulated in a 3D hydrogel matrix on a PEG diacrylate 
surface. Nanoscale microfluidic channels are employed to 
recapitulate the in vivo exchange of nutrients and waste in a 
liver-on-a-chip format. By modeling cytochrome P450 reac-
tion kinetics, the researchers were able to show the utility of 
this platform in pharmaceutical toxicology screening. Others 
have suggested scaling up such a system for use in hepatocyte 
encapsulation in vivo.77
Bone Regeneration
Clinical need. By 2020, it is expected that 9.3% of adults 
in the United States will suffer from osteoarthritis.78 The cur-
rent generation of orthopedic implants is lacking in biofunc-
tionality, and it is imperative that steps are taken to better 
integrate host and implant. Micromotion caused by nonspe-
cific differentiation of cells at the host–implant boundary limits 
the lifespan of primary devices and causes damage to the sur-
rounding tissue.79 Additionally, modulus mismatch between 
titanium implants and much softer bone causes tissue wastage 
and compounds the need for secondary surgery.80 In order to 
maximize the lifespan of primary orthopedic implants, cel-
lular differentiation at the host–implant boundary must be 
controlled while implant modulus must be matched to native 
tissue to encourage regeneration.
Bone ECM. Bone is primarily composed of bone matrix, 
interspersed by cells and vasculature. Eighty percent of the 
total bone mass of an adult skeleton is made up of cortical 
bone, characterized by parallel alignment of type I colla-
gen embedded in GAG gel and arranged into osteons. The 
remaining 20% by weight is composed of internal cancellous, 
or spongy, bone characterized by significant porosity and 
haphazard arrangement of collagen fibers.22 The inorganic 
composition of bone, responsible for much of its mechanical 
strength, is composed of carbonated hydroxyapatite. Bone 
matrix is continually degraded by osteoclasts and remodeled 
by osteoblasts laying down nonmineralized osteoid. Osteo-
blasts then secrete vesicles containing alkaline phosphatases, 
which cleave osteoid terminal phosphates and act as foci 
for hydroxyapetate crystal formation shown diagrammati-
cally in Figure 6 panel A. During this continuous process of 
bone remodeling, osteoblasts may become trapped in their 
own matrix, triggering differentiation into osteocytes of ill-
defined function.81
Bone tissue engineering. Tissue engineering of bone tis-
sue presents an interesting situation. Orthopedic implants are 
routinely used in surgery, and the clinical limitations of such 
devices are increasingly relevant.80 Thus, a great deal of tis-
sue engineering research has investigated the driving factors 
behind bone differentiation. For example, it has long been 
known that MSC differentiation into osteoblast, chondro-
cyte, or adipocyte lineage can be controlled by focal adhesion 
size and cell spreading.82 More recent research has shown that 
MSC differentiation can be directed toward osteogenic lineage 
through nanoscale disorder26 as well as nanoscale pits and pil-
lars, Figure 6 panel B.83 It is thought that such features mimic 
the osteoclast resorption pits created during bone remodeling. 
Hence, there is a great deal of effort into translating this basic 
research into improving bone formation along an implant’s 
edge.32 It is thought that techniques such as coating titanium 
implants in hydroxyapatite could direct MSC differentiation, 
reduce implant micromovements, and show very real ben-
efits in terms of patient quality of life in the short to medium 
term.84 However, as an orthopedic implant is designed to be a 
permanent feature, and not resorbed in the body, by definition 
it is not tissue engineering.
Various attempts have been made toward tissue 
engineering of bone; however, by and large these have been 
limited to correcting small defects without any major load-
bearing function. For example, Tarafder and colleagues fab-
ricated an interconnected porous tricalcium phosphate (TCP) 
scaffold with nanoscale SrO and MgO by direct 3D print-
ing.85 Although this scaffold showed a significant increase 
in osteoid-like new bone formation and accelerated healing 
through osteogenesis compared to pure TCP scaffolds, cur-
rent technology limits pore sizes to the microscale. Such large 
pores invariably compromise a scaffolds load-bearing capacity 
repesentative example shown in Figure 6 panel C. Similar 
attempts have been made with both bioresorbable Bioglass and 
polymeric scaffolds. In one study, Wu and colleagues intro-
duced ionic cobalt to mesoporous Bioglass scaffolds to mimic 
hypoxia and increase bone marrow–derived stem cell prolif-
eration and osteogenic differentiation.86 While studies of this 
nature show promise, current manufacturing techniques limit 
the translation of insights from 2D osteoblast culture into 3D 
scaffolds. However, self-assembling peptide nanofiber scaf-
folds are beginning to see utility for  osteointegration of dental 
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Figure 6. schematic of bone tissue remodeling. osteoclasts degrade old mineralized bone creating resorption pits. These pits are thought to recruit 
osteoblasts, which lay down new unmineralized matrix. Panel B shows nanopits produced in acrylic polymer, thought to reflect resorption pits and known 
to recapitulate bone formation in vitro.26 Bar is 1 μm. Mature osteoblasts secrete alkaline phosphatase to allow crystallization of hydroxyapatite and 
mineralization of new matrix. Panel C shows a macroporous poly(glycolic co-lactic) acid scaffold often used in solid bone engineering. such scaffolds 
can be functionalized with hydroxyapatite nanocrystals to aid mineralization.41 Bar is 10 μm.
implants, and with appropriate improvements to mechanical 
strength (Table 2), it is possible that such scaffolds could 
translate into orthopedic implant surgery.87
Future Prospects
As the ECM drives the initial complexity of a developing 
organ, it is necessary to understand and reproduce this matrix 
to help recapitulate complexity in tissue engineering. A cell’s 
extracellular environment is a complex milieu of growth fac-
tors, cytokines, morphogens, and biophysical cues. As many 
of these natural differentiative cues are in the order of sev-
eral nanometers, synthetic nanoscale materials should be 
incorporated into tissue engineering scaffolds. Over the past 
several years, the synthesis of new synthetic nanostructures 
and their incorporation into existing macro- and microscale 
scaffolds has led to improvements in our ability to produce a 
true biomimetic microenvironment. In addition, the utility of 
nanocomposites in overcoming matrix limitations in current 
biomaterials is becoming apparent.
However, major challenges still exist in the use nano-
technologies to engineer complex tissues. Foremost is the need 
for systematic studies into the biocompatibility and biodegra-
dation of newly synthesized nanotechnologies before they can 
be incorporated into clinical trials.
The interaction of cells with various nanotopographies 
has been studied extensively, and efforts have been made 
in the creation of complex monolayers of functional tis-
sues. However, major challenges remain in the scaling up 
of nanopatterning technologies for use in 3D scaffolds. One 
possibility is that direct 3D printing technologies will allow 
nanoscale resolution in the near future. Another, perhaps 
more exciting, possibility is that self-assembling peptides 
and hydrogels will be utilized in more applications. Such 
bottom-up manufacturing techniques allow nanoscale cues 
to be incorporated into monomers, in the form of adhe-
sion sequences, morphogens, or topographical cues. Mono-
mer self-assembly can then be finely tuned by modifying 
biochemical and biophysical parameters, allowing precise 
control over the seeded cells microenvironment. Integrated 
biomimetic approaches such as these will surely be required 
to deliver on the promises made by tissue engineering and 
regenerative medicine.
Cassidy
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